|
1.
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar
|
|
2.
|
Heinlein CA and Chang C: Androgen receptor
in prostate cancer. Endocr Rev. 25:276–308. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Loblaw DA, Virgo KS, Nam R, Somerfield MR,
Ben-Josef E, Mendelson DS, Middleton R, Sharp SA, Smith TJ, Talcott
J, Taplin M, Vogelzang NJ, Wade JL III, Bennett CL and Scher HI;
American Society of Clinical Oncology: Initial hormonal management
of androgen-sensitive metastatic, recurrent, or progressive
prostate cancer: 2006 update of an American Society of Clinical
Oncology practice guideline. J Clin Oncol. 25:1596–1605. 2007.
View Article : Google Scholar
|
|
4.
|
Petrylak DP, Tangen CM, Hussain MH, et al:
Docetaxel and estramustine compared with mitoxantrone and
prednisone for advanced refractory prostate cancer. N Engl J Med.
351:1513–1520. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Tannock IF, de Wit R, Berry WR, Horti J,
Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I,
Rosenthal MA and Eisenberger MA; TAX 327 Investigators: Docetaxel
plus prednisone or mitoxantrone plus prednisone for advanced
prostate cancer. N Engl J Med. 351:1502–1512. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Zheng X, Cui XX, Gao Z, et al:
Atorvastatin and celecoxib in combination inhibits the progression
of androgen-dependent LNCaP xenograft prostate tumors to androgen
independence. Cancer Prev Res. 3:114–124. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Zheng X, Cui XX, Avila GE, Huang MT, Liu
Y, Patel J, Kong AN, Paulino R, Shih WJ, Lin Y, Rabson AB, Reddy BS
and Conney AH: Atorvastatin and celecoxib inhibit prostate PC-3
tumors in immunodeficient mice. Clin Cancer Res. 13:5480–5487.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Jacobs EJ, Rodriguez C, Bain EB, Wang Y,
Thun MJ and Calle EE: Cholesterol-lowering drugs and advanced
prostate cancer incidence in a large U.S. cohort. Cancer Epidemiol
Biomarkers Prev. 16:2213–2217. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Hamilton RJ, Banez LL, Aronson WJ, Terris
MK, Platz EA, Kane CJ, Presti JC Jr, Amling CL and Freedland SJ:
Statin medication use and the risk of biochemical recurrence after
radical prostatectomy: results from the Shared Equal Access
Regional Cancer Hospital (SEARCH) Database. Cancer. 116:3389–3398.
2010. View Article : Google Scholar
|
|
10.
|
Murtola T, Tammela TLJ, Lahtela J and
Auvinen A: Cholesterol-lowering drugs and prostate cancer risk: a
population-based case-control study. Cancer Epidemiol Biomarkers
Prev. 16:2226–2232. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Platz EA, Leitzmann MF, Visvanathan K, et
al: Statin drugs and risk of advanced prostate cancer. J Natl
Cancer Inst. 98:1819–1825. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Bañez LL, Klink JC, Jayachandran J, Lark
AL, Gerber L, Hamilton RJ, Masko EM, Vollmer RT and Freedland SJ:
Association between statins and prostate tumor inflammatory
infiltrate in men undergoing radical prostatectomy. Cancer
Epidemiol Biomarkers Prev. 19:722–728. 2010.PubMed/NCBI
|
|
13.
|
Cheng I, Liu X, Plummer SJ, Krumroy LM,
Casey G and Witte JS: COX2 genetic variation, NSAIDs, and advanced
prostate cancer risk. Br J Cancer. 97:557–561. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Stock D, Groome PA and Siemens DR:
Inflammation and prostate cancer: a future target for prevention
and therapy? Urol Clin North Am. 35:117–130. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Cerhan JR, Torner JC, Lynch CF, et al:
Association of smoking, body mass, and physical activity with risk
of prostate cancer in the Iowa 65+ Rural Health Study (United
States). Cancer Causes Control. 8:229–238. 1997.
|
|
16.
|
Wannamethee SG, Shaper AG and Walker M:
Physical activity and risk of cancer in middle-aged men. Br J
Cancer. 85:1311–1316. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Friedenreich CM, McGregor SE, Courneya KS,
Angyalfi SJ and Elliott FG: Case-control study of lifetime total
physical activity and prostate cancer risk. Am J Epidemiol.
159:740–749. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Patel AV, Rodriguez C, Jacobs EJ, Solomon
L, Thun MJ and Calle EE: Recreational physical activity and risk of
prostate cancer in a large cohort of US men. Cancer Epidemiol
Biomarkers Prev. 14:275–279. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Nilsen TI, Romundstad PR and Vatten LJ:
Recreational physical activity and risk of prostate cancer: a
prospective population-based study in Norway (the HUNT study). Int
J Cancer. 119:2943–2947. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Orsini N, Bellocco R, Bottai M, Pagano M,
Andersson SO, Johansson JE, Giovannucci E and Wolk A: A prospective
study of lifetime physical activity and prostate cancer incidence
and mortality. Br J Cancer. 101:1932–1938. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Antonelli JA, Jones LW, Bañez LL, Thomas
JA, Anderson K, Taylor LA, Gerber L, Anderson T, Hoyo C, Grant D
and Freedland SJ: Exercise and prostate cancer risk in a cohort of
veterans undergoing prostate needle biopsy. J Urol. 182:2226–2231.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Zheng X, Cui XX, Huang MT, Liu Y, Shih WJ,
Lin Y, Lu YP, Wagner GC and Conney AH: Inhibitory effect of
voluntary running wheel exercise on the growth of human pancreatic
Panc-1 and prostate PC-3 xenograft tumors in immunodeficient mice.
Oncol Rep. 19:1583–1588. 2008.PubMed/NCBI
|
|
23.
|
Lindsey JK: Models for Repeated
Measurments. Claredon Press; Oxford: 1993
|
|
24.
|
Zhang JY, Wang Y, Dudkowski C, Yang D,
Chang M, Yuan J, Paulson SK and Breau AP: Characterization of
metabolites of celecoxib in rabbits by liquid chromatography/tandem
mass spectrometry. J Mass Spectrom. 35:1259–1270. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Black AE, Hayes RN, Roth BD, Woo P and
Woolf TF: Metabolism and excretion of atorvastatin in rats and
dogs. Drug Metab Dispos. 27:916–923. 1999.PubMed/NCBI
|
|
26.
|
Lins RL, Matthys KE, Verpooten GA, Peeters
PC, Dratwa M, Stolear JC and Lameire NH: Pharmacokinetics of
atorvastatin and its metabolites after single and multiple dosing
in hypercholesterolaemic haemodialysis patients. Nephrol Dial
Transplant. 18:967–976. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Reddy BS, Wang CX, Kong AN, Khor TO, Zheng
X, Steele VE, Kopelovich L and Rao CV: Prevention of
azoxymethane-induced colon cancer by combination of low doses of
atorvastatin, aspirin, and celecoxib in F 344 rats. Cancer Res.
66:4542–4546. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Reddy BS, Sugie S and Lowenfels A: Effect
of voluntary exercise on azoxymethane-induced colon carcinogenesis
in male F344 rats. Cancer Res. 48:7079–7081. 1988.PubMed/NCBI
|
|
29.
|
Cohen LA, Choi K, Backlund JY, Harris R
and Wang CX: Modulation of N-nitrosomethylurea induced mammary
tumorigenesis by dietary fat and voluntary exercise. In Vivo.
5:333–344. 1991.PubMed/NCBI
|
|
30.
|
Thompson HJ: Effects of physical activity
and exercise on experimentally-induced mammary carcinogenesis.
Breast Cancer Res Treat. 46:135–141. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Michna L, Wagner GC, Lou YR, Xie JG, Peng
QY, Lin Y, Carlson K, Shih WJ, Conney AH and Lu YP: Inhibitory
effects of voluntary running wheel exercise on UVB-induced skin
carcinogenesis in SKH-1 mice. Carcinogenesis. 27:2108–2115. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Beavers KM, Brinkley TE and Nicklas BJ:
Effect of exercise training on chronic inflammation. Clin Chim
Acta. 411:785–793. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Mathur N and Pedersen BK: Exercise as a
mean to control low-grade systemic inflammation. Mediators Inflamm.
Jan. 11–2009.(E-pub ahead of print).
|
|
34.
|
Cilla DD Jr, Whitfield LR, Gibson DM,
Sedman AJ and Posvar EL: Multiple-dose pharmacokinetics,
pharmacodynamics, and safety of atorvastatin, an inhibitor of
HMG-CoA reductase, in healthy subjects. Clin Pharmacol Ther.
60:687–695. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Lennernas H: Clinical pharmacokinetics of
atorvastatin. Clin Pharmacokinet. 42:1141–1160. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Davies NM, McLachlan AJ, Day RO and
Williams KM: Clinical pharmacokinetics and pharmacodynamics of
celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin
Pharmacokinet. 38:225–242. 2000. View Article : Google Scholar : PubMed/NCBI
|
